334 related articles for article (PubMed ID: 16257545)
1. Overview of marker vaccine and differential diagnostic test technology.
Henderson LM
Biologicals; 2005 Dec; 33(4):203-9. PubMed ID: 16257545
[TBL] [Abstract][Full Text] [Related]
2. Regulatory considerations for marker vaccines and diagnostic tests in the U.S.
Foley PL; Hill RE
Biologicals; 2005 Dec; 33(4):253-6. PubMed ID: 16257538
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnostic test technology: sensitivity and specificity, an OIE validation perspective.
Schmitt B
Biologicals; 2005 Dec; 33(4):211-3. PubMed ID: 16289686
[TBL] [Abstract][Full Text] [Related]
4. Marker vaccines and the impact of their use on diagnosis and prophylactic measures.
Vannie P; Capua I; Le Potier MF; Mackay DK; Muylkens B; Parida S; Paton DJ; Thiry E
Rev Sci Tech; 2007 Aug; 26(2):351-72. PubMed ID: 17892157
[TBL] [Abstract][Full Text] [Related]
5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
6. Three Rs potential in the development and quality control of immunobiologicals.
Halder M
ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
[TBL] [Abstract][Full Text] [Related]
7. [Biotechnology for the benefit of vaccination against viral diseases: a review].
van Oirschot JT
Tijdschr Diergeneeskd; 2002 Jan; 127(1):7-16. PubMed ID: 11795035
[TBL] [Abstract][Full Text] [Related]
8. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
Grubman MJ
Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
11. [Biotechnology and animal health].
Desmettre P
Rev Sci Tech; 1993 Jun; 12(2):355-68. PubMed ID: 8400382
[TBL] [Abstract][Full Text] [Related]
12. OIE standards for vaccines and future trends.
Edwards S
Rev Sci Tech; 2007 Aug; 26(2):373-8. PubMed ID: 17892158
[TBL] [Abstract][Full Text] [Related]
13. [Evolution of IGRA researches].
Ariga H; Harada N
Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
[TBL] [Abstract][Full Text] [Related]
14. Novel vaccines from biotechnology.
Rogan D; Babiuk LA
Rev Sci Tech; 2005 Apr; 24(1):159-74. PubMed ID: 16110886
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered vaccines: an overview.
Dertzbaugh MT
Plasmid; 1998; 39(2):100-13. PubMed ID: 9514708
[TBL] [Abstract][Full Text] [Related]
16. Biological safety concepts of genetically modified live bacterial vaccines.
Frey J
Vaccine; 2007 Jul; 25(30):5598-605. PubMed ID: 17239999
[TBL] [Abstract][Full Text] [Related]
17. Marker vaccine strategies and candidate CSFV marker vaccines.
Dong XN; Chen YH
Vaccine; 2007 Jan; 25(2):205-30. PubMed ID: 16934915
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
Brennan FR; Dougan G
Vaccine; 2005 May; 23(24):3210-22. PubMed ID: 15837222
[TBL] [Abstract][Full Text] [Related]
19. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
20. The place of marker vaccines in control and eradication of animal diseases--aspects of comparative interest.
Pastoret PP
Dev Biol (Basel); 2005; 121():181-8. PubMed ID: 15962481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
